Coverage · Live since 1 July 2026
Medicare now covers weight-loss drugs, with a $50 copay
For the first time, Medicare covers weight-loss medication. The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027 and caps the copay for eligible Part D enrollees at $50 a month. If you are eligible, this is almost certainly cheaper than anything in our price database.
What it covers
Per Medicare.gov, three products: Foundayo, Wegovy and the Zepbound KwikPen (not Zepbound vials, Ozempic or Mounjaro), for eligible Part D enrollees with a BMI of 35 or more, or a lower BMI with listed conditions. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge; their Part D plan might cover a GLP-1. The programme is structured as a time-limited bridge — a pilot with a defined end date, not a permanent benefit — ahead of broader Part D arrangements.
Why it changes the calculation completely
A $50 monthly copay is below every compounded price in our dataset, which starts at $129 a month all-in for tirzepatide and $109 for semaglutide, and neither competes with $50 for an FDA-approved product.
So the honest advice to any Medicare-eligible reader is: establish your eligibility for the Bridge before reading another page of this site. Every cash price we publish is aimed at people without a coverage route, and if you have one, our rankings are the wrong tool.
The parts worth reading carefully
It is time-limited. The programme runs to the end of 2027, and what happens after is a policy question nobody can answer today. Anyone building a multi-year treatment plan around it should know that.
It is eligibility-gated: per Medicare.gov, a BMI of 35 or more, or a BMI of 30 or 27 and above with listed conditions, not weight loss on request. The documentation requirements are the usual ones, and our insurance and appeals guide covers the prior-authorisation sequence that applies.
What it means for compounded programs
It removes the Medicare-eligible population from the compounded market almost entirely, which is a meaningful share of the people with the highest clinical need. Combined with roughly $350 brand pricing through the federal platform, the compounded lane is being squeezed from both ends at once — by an approved product that got cheaper and by a coverage route that made it free-ish for the people who most need it.
Verified (Medicare.gov and CMS pages read October 15, 2026). Regulatory positions, prices and trial results move — check the primary source before relying on a date. Compounded tirzepatide and semaglutide are not FDA-approved products.
Related: which state Medicaid programs stopped covering GLP-1s for weight loss, and what cash pay costs at each dose.
Questions
Does Medicare cover weight-loss drugs in 2026?
Partly. The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027 and, per Medicare.gov, covers Foundayo, Wegovy and the Zepbound KwikPen only, for eligible Part D enrollees with obesity or overweight and listed conditions. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge.
What is the copay for Medicare GLP-1 coverage?
A maximum of $50 a month for an eligible beneficiary, through December 31, 2027. The Bridge sits outside the standard Part D benefit, so there is no deductible.
Is Medicare coverage cheaper than compounded GLP-1s?
Substantially. A $50 copay is below every compounded price in this database, which starts at $129 a month all-in for tirzepatide. If you are eligible, coverage beats every cash price we publish.
How long does the Medicare GLP-1 Bridge last?
It is a time-limited pilot running from 1 July 2026 to 31 December 2027. What replaces it is an open policy question.